Brought to you by 
Pfizer to acquire King for $3.56bn, gains pain portfolio
09 Dec 2020
Executive Summary
Pfizer Inc. has agreed to pay $14.25 (a 42% premium) for each outstanding share of specialty pharmaco King Pharmaceuticals Inc., valuing the acquisition at $3.56bn.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer to acquire King for $3.56bn, gains pain portfolio
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice